In the follow-up, a phase II study was performed (NCT03931291) to investigate the efficacy and safety of APR-246 in combination with azacitidine for TP53-mutated MDS or AML patients as post-hematopoietic stem-cell transplantation (HSCT) maintenance therapy [97]. This evidence concerns the gene TP53 and myelodysplastic syndrome.